news
New nanomachines developed to deliver cancer drugs to hard-to-reach areas
In a recent study in mice, researchers have found a way to deliver specific drugs to parts of the body that are exceptionally difficult to access.
List view / Grid view
Biopharmaceuticals
article
Network-driven drug discovery
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
news
Sartorius Stedim Biotech introduces BIOSTAT® RM TX with Flexsafe® RM TX for producing consistent quality cellular products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...
product
BIOSTAT® RM TX and Flexsafe® RM TX Bags
14 February 2019 | By Sartorius
The BIOSTAT® RM TX system consists of an automated control unit and a rocking platform, for gently agitating a single-use Flexsafe® RM bag...
whitepaper
Application note: Rapidly isolate high-producing clones
Find out how to streamline Cell Line Development by identifying high-producing clones with monoclonality assurance in one day.
whitepaper
Application note: Enabling single-software multiple attribute methodology (MAM) for the assessment of biopharmaceutical product quality attributes
Development and production of biopharmaceuticals is complex. Even minor impurities, or changes in attributes such as glycosylation or charge heterogeneity, can have a profound impact on the safety and efficacy of the final product. Traditionally, multiple analytical techniques have been required to assess the full range of biopharmaceutical product attributes.…
whitepaper
Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
whitepaper
Application note: A novel solution to expedite antibody discovery
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
whitepaper
Application note: Transforming your bioanalysis operations – is a lack of insight slowing you down?
Many bioanalytical labs work with a crowded and siloed set of systems and processes. From part electronic to part paper-based workflows to standalone point-solutions, the result is a lack of insight into data and slower reporting and results handling.
article
The role of drug transporters in phenotypic screening
The relative failure of molecular target-based drug discovery has led to a return to phenotypic screening. Targets that are intracellular necessitate their drug ligands to pass through plasma membranes, where the protein:lipid ratio is often 3:1 by mass and at least 1:1 by area. The widespread view that most of…
news
Method developed to facilitate effective protein drugs with fewer side effects
Researchers in Denmark have developed a method that enables better tailored pharmaceuticals with fewer side effects.
article
Expert view: Screen everything. See everything.
Explore the full kinetic and epitope diversity of large antibody libraries with high throughput Array SPR (Surface Plasmon Resonance).
article
Upstream cell culture processes for the production of therapeutic proteins
The upstream process encompasses the initial transfections of a gene of interest into host cells, the cloning of cell lines with desirable characteristics (e.g. high productivity) and subsequent scale-up to large scale manufacture.
news
Revolutionary eye drops to treat age-related macular degeneration
Scientists are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD)...
news
SMi’s 13th Annual ADMET conference 2018 brochure released
The annual ADMET conference is returning to London, UK for its 13th year running and will be taking place at the Holiday Inn Kensington Forum on the 9 and 10 July 2018...
